| Literature DB >> 27725107 |
Jung-Ah Lim1, Soon-Tae Lee1, Jangsup Moon1, Jin-Sun Jun1, Byeong-Su Park1, Jung-Ick Byun2, Jun-Sang Sunwoo3, Kyung-Il Park4, Keun-Hwa Jung1, Ki-Young Jung1, Sang Kun Lee1, Kon Chu5.
Abstract
Low-dose interleukin-2 (IL-2) restores the balance of regulatory and effector T cells. We aimed to determine the feasibility of low-dose IL-2 as a treatment for refractory autoimmune encephalitis (AE). Ten patients who had received low-dose IL-2 were retrospectively identified. We observed an improvement in the modified Rankin Scale scores of six patients at the last follow-up compared with the scores at the initiation of low-dose IL-2 (p=0.014). One patient experienced treatment-related grade 3 neutropenia. Overall, low-dose IL-2 is a feasible and relatively safe treatment for AE patients who are refractory to the first- and second-line immunotherapies.Entities:
Keywords: Autoimmune encephalitis; Encephalitis; Low-dose IL-2; Regulatory T cell
Mesh：
Substances：
Year: 2016 PMID： 27725107 DOI： 10.1016/j.jneuroim.2016.09.001
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478